C4 Therapeutics Inc (NASDAQ:CCCC) shares, rose in value on Friday, May 30, with the stock price down by -5.30% to the previous day’s close as strong demand from buyers drove the stock to $1.25.
Actively observing the price movement in the last trading, the stock closed the session at $1.32. Referring to stock’s 52-week performance, its high was $7.66, and the low was $1.09. On the whole, CCCC has fluctuated by -23.78% over the past month.
With the market capitalization of C4 Therapeutics Inc currently standing at about $88.76 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 5.37M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CCCC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CCCC currently trading nearly -13.04% and -17.09% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.41, while the 7-day volatility ratio is showing 4.91% which for the 30-day chart, stands at 6.43%. Furthermore, C4 Therapeutics Inc (CCCC)’s beta value is 2.96, and its average true range (ATR) is 0.14.
A comparison of C4 Therapeutics Inc (CCCC) with its peers suggests the former has fared considerably weaker in the market. CCCC showed an intraday change of -5.30% in last session, and over the past year, it shrunk by -76.68%%.
Data on historical trading for C4 Therapeutics Inc (NASDAQ:CCCC) indicates that the trading volumes over the past 3 months, they’ve averaged 1.05 million. According to company’s latest data on outstanding shares, there are 70.99 million shares outstanding.
Nearly 23.61% of C4 Therapeutics Inc’s shares belong to company insiders and institutional investors own 80.35% of the company’s shares. The stock has fallen by -65.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CCCC stock heading into the next quarter.
